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Abstract
Recently, there have been several reports related to the adequacy of blood pressure (BP) control in
high-risk hypertensive patients. These aspects have been reviewed in the recently published
reappraisal of the European Society of Hypertension guidelines, and this short review comments on
and briefly extends the discussion of this situation. In summary, a low BP goal when cardiorenal
disease is advanced can be risky. However, attaining normal BP levels at earlier stages in the
cardiorenal continuum is probably totally adequate.
Introduction and context
The latest evidence supported by the most recent
comparative trials [1-6] has prompted a reconsideration
of the current guidelines for the management of
hypertension [7]. Consensus over the initiation of
antihypertensive treatment and blood pressure (BP)
goals is essential in order to optimize hypertension
management and outcomes. In addition, BP measure-
ment methods must be tested in order to establish the
optimal and most reliable approach for determining
accurate BP levels. Current recommendations are based
on the finding that a given difference in BP, as measured
in the clinic, results in a given difference in outcome, as
demonstrated by observational and interventional stu-
dies and their meta-analyses [8-10].
Recent advances
Guidelines recommend the use of antihypertensive drugs
in patients with grade 1 hypertension at low or moderate
cardiovascular (CV) risk – namely, when systolic BP
(SBP) is between 140 and 159 mm Hg or when diastolic
BP is between 90 and 99 mm Hg (or when both occur) –
provided that non-pharmacological treatment has
proven ineffective. Nevertheless, there is inconclusive
evidence of whether older persons with grade 1
hypertension, diabetics, or patients with coronary
disease and high normal BP should be treated [7].
Therefore, ongoing and future trials are necessary to set
up a more robust assessment of treatment benefits in
these patients (Table 1). Also, discussion about the most
adequate BP goals is emerging from a number of recent
studies. It seems reasonable, particularly given the results
of a number of prospective trials, that SBP should
be reduced to less than 140 mm Hg in the general
population of patients with grade 1 or 2 hypertension
and low or moderate total CV risk. Information on BP
thresholds and targets for drug treatment has also
resulted from post hoc analyses of event-based trials and
from studies on the effects of treatment on organ damage
of prognostic importance, although, admittedly, this is
weaker evidence. In the ONgoing Telmisartan Alone and
in combination with Ramipril Global Endpoint Trial
(ONTARGET) [3], favorable effects of BP reductions were
seen when initial SBP values were above 140 mm Hg,
even after adjusting for potential confounders, and a
greater BP reduction was usually accompanied by greater
CV protection. Conversely, the benefit was less obvious
and primarily limited to stroke patients in whom initial
SBP was in the range of 130 mm Hg [11]. The lack of
benefit observed in this trial was directly related to the
high CV risk of the population included. Consequently,
the recommendation of previous guidelines to aim for a
lower SBP goal (<130 mm Hg) in patients at very high
CV risk may be prudent but is not consistently supported
by trial evidence. In no randomized trial in diabetic
patients has SBP been reduced to below 130 mm Hg with
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below 130 mm Hg in patients with previous CV events
have produced controversial results (Table 2).
Finally, a close analysis of most of the relevant trials
suggests that the absence of benefit of antihypertensive
therapy in some trials might be due to the fact that some
patients have normal BP at trial entry. Enrollment of
patients into clinical trials on the basis of office-based BP
alone might no longer be appropriate. An increasing
amount of data is coming from clinical trials that include
patients who are evaluated by ambulatory monitoring of
BP [12-14]. The results of these studies may allow a
better assessment of trial eligibility. Moreover, they
identify the individuals with the lowest actual BP, who
thus are at higher risk of adverse effects of treatment.
Implications for clinical practice
The question of whether trials should include ambula-
tory BP monitoring and home BP monitoring as well as
conventional clinic measurements must be answered in
upcoming trials. Ambulatory BP values are known to
correlate with organ damage and CV events better than
clinic measurement does [15]. However, ambulatory BP
monitoring is not widely employed in trials, and when it
is employed, it is in a minor subgroup of patients only.
So far, when ambulatory BP was measured, the correla-
tion between the antihypertensive effect measured by
ambulatory and office BP appears to be quite different.
The proportion of hypertensive patients achieving
satisfactory BP control also differs depending on whether
BP is measured in the clinic or by ambulatory monitor-
ing. Comparative data are few and show discrepant
results: some controlled studies indicate an easier BP
control by clinic measurement (<140/90 mm Hg) than
by ambulatory BP monitoring (<130/80 mm Hg) [16],
whereas Spanish registry data [12,17] suggest that almost
half of all patients with office-diagnosed hypertension
are normotensive when assessed by ambulatory BP
monitoring. Hence, future trials should use ambulatory
BP monitoring alongside conventional clinic BP
measurements.
Abbreviations
BP, blood pressure; CV, cardiovascular; SBP, systolic
blood pressure.
Competing interests
The authors declare that they have no competing
interests.
References
1. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J,
Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M,
Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS,
Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B: Effects of a
fixed combination of perindopril and indapamide on
Table 1. Consensus in treatment initiation [7]
1. Although trial evidence is scanty, it appears reasonable to recommend that, in grade 1 hypertensives (systolic blood pressure [SBP] of 140-159 mm Hgo r
diastolic blood pressure [DPB] of 90-99 mm Hg) at low or moderate risk, drug therapy should be started after a suitable period with lifestyle changes.
A more prompt initiation of treatment is advisable if grade 1 hypertension is associated with a high level of risk or if hypertension is grade 2 or 3.
2. In patients with high normal blood pressure (BP) (SBP of 130-139 mm Hg or DPB of 85-89 mm Hg) uncomplicated by diabetes or previous cardiovascular
events, no trial evidence of treatment benefits, except for a delayed onset of hypertension (crossing the 140/90 mm Hg cutoff) is available.
3. Initiation of antihypertensive drug therapy in diabetic patients with high normal BP is currently unsupported by prospective trial evidence. For the time
being, it appears prudent to recommend treatment initiation in high normal BP diabetic patients if subclinical organ damage (particularly microalbuminuria or
proteinuria) is present.
4. Trial evidence concerning antihypertensive drug treatment in patients with previous cardiovascular events in the absence of hypertension is controversial,
and further trials must be completed before firm recommendations can be given.
5. Early BP-lowering treatment, before organ damage develops or becomes irreversible or cardiovascular events occur, appears to be a prudent
recommendation.
Table 2. Consensus in blood pressure goals of treatment [7]
1. On the whole, there is sufficient evidence to recommend that systolic blood pressure (SBP) be lowered to below 140 mm Hg (and diastolic blood
pressure [DBP] to below 90 mm Hg) in all hypertensive patients, both those at low moderate risk and those at high risk. Evidence is missing only in older
hypertensive patients, in whom the benefit of lowering SBP to below 140 mm Hg has never been tested in randomized trials.
2. The recommendation of previous guidelines to aim for a lower SBP goal (<130 mm Hg) in diabetic patients and in patients at very high cardiovascular risk
(previous cardiovascular events) may be wise, but it is not consistently supported by trial evidence. In no randomized trial in diabetic patients has SBP been
reduced to below 130 mm Hg with proven benefits, and trials in which SBP was lowered to below 130 mm Hg in patients with previous cardiovascular
events have produced controversial results.
3. Despite their obvious limitations and a lower strength of evidence, post hoc analyses of trial data indicate a progressive reduction of incidence of
cardiovascular events with progressive lowering of SBP to about 120 mm Hg and DBP to about 75 mm Hg, although the additional benefit at low BP values
becomes rather small. A J-curve phenomenon is unlikely to occur until lower values are reached, except perhaps in patients with advanced atherosclerotic
artery diseases.
4. On the basis of current data, it may be prudent to recommend lowering SBP/DBP to values within the range of 130-139/80 to 85 mm Hg (in particular, to
lower values in this range) in all hypertensive patients. However, additional critical evidence from specific randomized trials is desirable.
Page 2 of 3
(page number not for citation purposes)
f1000 Medicine Reports 2010, 2:19 http://f1000.com/reports/medicine/content/2/19macrovascular and microvascular outcomes in patients with
type 2 diabetes mellitus (the ADVANCE trial): a randomised
controlled trial. Lancet 2007, 370:829-40.
f1000 Factor 3.2 Recommended
Evaluated by Phyllis August 29 Nov 2007, Jerome Fleg 13 Dec 2007
2. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A,
Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators:
Benazepril plus amlodipine or hydrochlorothiazide for
hypertension in high-risk patients. NE n g lJM e d2008,
359:2417-28.
f1000 Factor 6.0 Must Read
Evaluated by Raymond Townsend 07 Jan 2009
3. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L,
Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C:
Telmisartan, ramipril, or both in patients at high risk for
vascular events. N Engl J Med 2008, 358:1547-59.
f1000 Factor 10.0 Exceptional
Evaluated by Csaba Kovesdy 15 Apr 2008, Sripal Bangalore 23 Apr
2008, Enyu Imai 06 May 2008, Ernie Esquivel 14 May 2008
4. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant
subjects with cardiovascular Disease (TRANSCEND) Investigators,
Y u s u fS ,T e oK ,A n d e r s o nC ,P o g u eJ ,D y a lL ,C o p l a n dI ,
Schumacher H, Dagenais G, Sleight P: Effects of the angiotensin-
receptor blocker telmisartan on cardiovascular events in
high-risk patients intolerant to angiotensin-converting
enzyme inhibitors: a randomised controlled trial. Lancet
2008, 372:1174-83.
5. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA,
Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP,
Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C,
Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C,
Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, et al.:
Telmisartan to prevent recurrent stroke and cardiovascular
events. N Engl J Med 2008, 359:1225-37.
6. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D,
Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A,
Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study
Group: Treatment of hypertension in patients 80 years of age
or older. N Engl J Med 2008, 358:1887-98.
Changes Clinical Practice
f1000 Factor 10.7 Exceptional
Evaluated by Deepak Bhatt 14 Apr 2008, Ramachandran S Vasan
15 Apr 2008, Jerome Fleg 18 Apr 2008, Annemarie Hennessy 29
Apr 2008, Ernesto Schiffrin 02 May 2008, Wilbert Aronow 07 May
2008, Kazuomi Kario 03 Jun 2008
7. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M,
Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S,
Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE,
Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P,
Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE,
Struijker-Boudier HA, Van Zwieten PA, et al.: Reappraisal of
European guidelines on hypertension management: a
European Society of Hypertension Task Force document.
Blood Press 2009, 18:308-47.
8. Prospective Studies Collaboration: Age-specific relevance of usual
blood pressure to vascular mortality: a meta-analysis of
individual data for one million adults in 61 prospective
studies. Lancet 2002, 360:1903-13.
9. Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects
of different blood-pressure-lowering regimens on major
cardiovascular events: results of prospectively designed
overviews of randomised trials. Lancet 2003, 362:1527-35.
10. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA,
Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure,
stroke, and coronary heart disease. Part 2: short-term
reductions in blood pressure: overview of randomised drug
trials in their epidemiological context. Lancet 1990, 335:827-38.
11. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R,
Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T,
Yusuf S; ONTARGET investigators: Prognostic value of blood
pressure in patients with high vascular risk in the Ongoing
Telmisartan Alone and in combination with Ramipril Global
Endpoint Trial study. J Hypertens 2009, 27:1360-9.
12. Banegas JR, Messerli FH, Waeber B, Rodríguez-Artalejo F, de la
Sierra A, Segura J, Roca-Cusachs A, Aranda P, Ruilope LM:
Discrepancies between office and ambulatory blood pres-
sure: clinical implications. Am J Med 2009, 122:1136-41.
13. Banegas JR, Segura J, de la Sierra A, Gorostidi M, Rodríguez-Artalejo F,
Sobrino J, de la Cruz JJ, Vinyoles E, del Rey RH, Graciani A,
Ruilope LM; Spanish Society of Hypertension ABPM Registry
Investigators: Gender differences in office and ambulatory
control of hypertension. Am J Med 2008, 121:1078-84.
14. de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M,
de la Cruz JJ, Sobrino J, Llisterri JL, Alonso J, Vinyoles E, Pallarés V,
Sarría A, Aranda P, Ruilope LM; Spanish Society of Hypertension
Ambulatory Blood Pressure Monitoring Registry Investigators: Pre-
valence and factors associated with circadian blood pressure
patterns in hypertensive patients. Hypertension 2009, 53:466-72.
15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R,
Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S,
Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA,
Z a n c h e t t iA ,V a h a n i a nA ,C a m mJ ,D eC a t e r i n aR ,D e a nV ,
Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I,
Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M,
Widimsky P, et al.: 2007 Guidelines for the Management of
Arterial Hypertension: The Task Force for the Management
of Arterial Hypertension of the European Society of
Hypertension (ESH) and of the European Society of
Cardiology (ESC). J Hypertens 2007, 25:1105-87.
16. Mancia G, Parati G: Office compared with ambulatory blood
pressure in assessing response to antihypertensive treat-
ment: a meta-analysis. J Hypertens 2004, 22:435-45.
17. Banegas JR, Segura J, Sobrino J, Rodríguez-Artalejo F, de la Sierra A,
de la Cruz JJ, Gorostidi M, Sarría A, Ruilope LM; Spanish Society of
Hypertension Ambulatory Blood Pressure Monitoring Registry
Investigators: Effectiveness of blood pressure control outside
the medical setting. Hypertension 2007, 49:62-8.
Page 3 of 3
(page number not for citation purposes)
f1000 Medicine Reports 2010, 2:19 http://f1000.com/reports/medicine/content/2/19